In fact, one of the common problems associated with the currently available Plk1 ATP-competitive inhibitors is their low degree of selectivity against other kinases24, including two that are closely related, Plk2 and Plk3, with possible tumor-suppressor function40,41. Here, PLK2 is linked to neoplasm.